{"protocolSection": {"identificationModule": {"nctId": "NCT03968978", "orgStudyIdInfo": {"id": "D5180C00011"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Tezepelumab Home Use Study", "officialTitle": "A Multicenter, Randomized, Open-label, Parallel Group, Functionality, and Performance Study of an Accessorized Pre-filled Syringe and Autoinjector With Home-administered Subcutaneous Tezepelumab in Adolescent and Adult Subjects With Severe Asthma (PATH-HOME)", "acronym": "PATH-HOME"}, "statusModule": {"statusVerifiedDate": "2021-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-05-21", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-06-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-06-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2019-04-30", "studyFirstSubmitQcDate": "2019-05-29", "studyFirstPostDateStruct": {"date": "2019-05-30", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2021-05-21", "resultsFirstSubmitQcDate": "2021-07-09", "resultsFirstPostDateStruct": {"date": "2021-07-29", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-07-09", "lastUpdatePostDateStruct": {"date": "2021-07-29", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}, "collaborators": [{"name": "Amgen", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "This is a multicenter, randomized, open-label, parallel-group study designed to assess healthcare provider and subject/caregiver reported functionality and performance of a single-use accessorized pre-filled syringe (APFS) or autoinjector (AI) with a fixed 210 mg dose of tezepelumab administered subcutaneously in the clinic and in an at-home setting.", "detailedDescription": "The study will consist of a screening/run-in period of up to 2 weeks and a treatment period of 24 weeks, followed by a post-treatment follow-up period of 12 weeks. During the treatment period, one dose of 210 mg tezepelumab will be administered via a single-use APFS or AI subcutaneously (SC) every 4 weeks (Q4W) starting at Visit 2 (Week 0) until Visit 7 (Week 20). Subjects will be administered tezepelumab at the site during Visits 2 (Week 0), 3 (Week 4), 4 (Week 8) and 7 (Week 20). At-home administration of tezepelumab will occur during Visit 5 (Week 12) and Visit 6 (Week 16). Each device will be assessed separately using descriptive presentations."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma, Severe Uncontrolled Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "Subjects will be randomized 1:1 to either an accessorized pre-filled syringe or an autoinjector. Both will be administered 210 mg tezepelumab subcutaneously.", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 216, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Tezepelumab (AI)", "type": "EXPERIMENTAL", "description": "Tezepelumab subcutaneous injection, administered by Autoinjector (AI) device.", "interventionNames": ["Biological: Tezepelumab (AI)"]}, {"label": "Tezepelumab (APFS)", "type": "EXPERIMENTAL", "description": "Tezepelumab subcutaneous injection, administered by Accessorized pre-filled syringe (APFS).", "interventionNames": ["Biological: Tezepelumab (APFS)"]}], "interventions": [{"type": "BIOLOGICAL", "name": "Tezepelumab (APFS)", "description": "Tezepelumab subcutaneous injection, administered by Accessorized pre-filled syringe (APFS).", "armGroupLabels": ["Tezepelumab (APFS)"]}, {"type": "BIOLOGICAL", "name": "Tezepelumab (AI)", "description": "Tezepelumab subcutaneous injection, administered by Autoinjector (AI) device.", "armGroupLabels": ["Tezepelumab (AI)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Proportions of HCPs and Subjects/Caregivers Who Successfully Administered Tezepelumab in Clinic or at Home by Device Type", "description": "Successful administration is defined as an injection completed, based on a used/returned (HCP or subject/caregiver) answer of YES to all 5 questions in the administration questionnaire, and satisfactory in vitro evaluation of returned/evaluated devices.", "timeFrame": "Week 0, Week 4, Week 8, Week 12, Week 16, Week 20"}], "secondaryOutcomes": [{"measure": "Proportions of Used/Returned Devices That Pass Functional Tests and Visual Inspection and Showed no Evidence of Malfunction", "description": "Devices that passed functional tests and visual inspection and showed no evidence of malfunction will be evaluated as functional.\n\nPercentages have been calculated by using the number of used and returned devices at specified visit as denominator.\n\nNote: A few participants had missing devices. One participant had two AI devices at Week 4.", "timeFrame": "Week 0, Week 4, Week 8, Week 12, Week 16, Week 20"}, {"measure": "Proportions of Devices That Have Been Reported as Malfunctioning (Product Complaints)", "description": "Performance is measured by the proportion of APFS or AI devices that have been reported as malfunctioning (i.e. via Product Complaints).\n\nPercentages have been calculated by using the number of used and returned devices at specified visit as denominator.\n\nNote: A few participants had missing devices. One participant had two AI devices at Week 4.", "timeFrame": "Week 0, Week 4, Week 8, Week 12, Week 16, Week 20"}, {"measure": "Change From Baseline in Asthma Control Questionnaire-6 (ACQ-6) Score", "description": "The ACQ-6 captures asthma symptoms and short-acting \u03b22-agonist use via subject-report. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The ACQ-6 score is the mean of the responses.", "timeFrame": "Baseline (Week 0), Week 4, Week 8, Week 12, Week 16, Week 20 and Week 24"}, {"measure": "Serum Trough Concentrations", "description": "PK serum samples were collected pre-dose on dosing visits", "timeFrame": "Baseline (Week 0), Week 4, Week 20 and Week 24 (EOT)"}, {"measure": "Anti-drug Antibodies (ADA)", "description": "Anti-drug antibodies (ADA) responses at baseline and/or post baseline. Treatment-induced ADA positive is defined as ADA negative at baseline and post-baseline ADA positive. Treatment-boosted ADA positive is defined as baseline positive ADA titre that was boosted to a 4-fold or higher-level following IP administration. Treatment-emergent ADA (TE-ADA) positive is defined as either treatment-induced ADA positive or treatment-boosted ADA positive. ADA incidence is the proportion of TE-ADA positive subjects in a population. Persistently positive is defined as ADA positive at \\>=2 post-baseline assessments (with \\>=16 weeks between first and last positive) or ADA positive at last post-baseline assessment. Transiently positive is defined as having at least one post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive", "timeFrame": "Pre-treatment on dosing days until end of follow-up (Week 36) per protocol"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female, age 12 to 80 years.\n* Documented physician-diagnosed asthma for at least 12 months.\n* Evidence of asthma as documented by post BD (albuterol/salbutamol) reversibility of FEV1 \u2265 12% AND \u2265200 mL (15-60 min after administration of 4 puffs of albuterol/salbutamol), documented either: in the previous 12 months prior to V1, OR demonstrated at V1, V1A, or at V2.\n* Documented history of current treatment with medium- or high-dose ICS for at least 6 months and at least one additional asthma controller medication according to standard practice of care. ICS dose must be greater than or equal to 500 \u03bcg/day fluticasone propionate dry powder formulation or equivalent daily.\n* Morning pre-BD FEV1 of \\>50% predicted normal at Visit 1, Visit 1A, or Visit 2.\n\nExclusion Criteria:\n\n* Clinically important pulmonary or systemic diseases other than asthma.\n* History of cancer except basal cell carcinoma, squamous cell carcinoma, or in situ carcinoma of the cervix within 12 months prior to Visit 1.\n* Acute upper or lower respiratory infection requiring antibiotics or antiviral medications finalized \\<2 weeks before Visit 1 or during screening/run-in period.\n* A helminth parasitic infection diagnosed within 6 months that is untreated or is unresponsive to the standard of care.\n* Smoking history of \u226510 pack years, (includes vaping and e-cigarettes)\n* History of chronic alcohol or drug abuse.\n* Tuberculosis requiring treatment within 12 months prior to V1.\n* History of HIV, Hepatitis B or Hepatitis C.\n* Receipt of any marketed or investigational biologic agent within 4 months or 5 half-lives (whichever is longer) prior to visit 1 or receipt of any investigational non-biologic agent within 30 days or 5 half-lives.\n* Bronchial thermoplasty in 24 months prior to V1.\n* Anaphylaxis or documented immune complex disease (Type III hypersensitivity reactions) to any biologic therapy.\n* Evidence of active liver disease (e.g. jaundice, AST, ALT or ALP \\>2 times upper limit of normal), ongoing liver disease or inexplicably elevated liver chemistry values.\n* Pregnant, breastfeeding or lactating women.\n* Non-leukocyte depleted whole blood transfusion in 120 days prior to visit 1.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "maximumAge": "80 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Sady A Alpizar, MD", "affiliation": "Clinical Research Trials of Florida, Inc.", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "Hoover", "state": "Alabama", "zip": "35244", "country": "United States", "geoPoint": {"lat": 33.40539, "lon": -86.81138}}, {"facility": "Research Site", "city": "Gilbert", "state": "Arizona", "zip": "85234", "country": "United States", "geoPoint": {"lat": 33.35283, "lon": -111.78903}}, {"facility": "Research Site", "city": "Northridge", "state": "California", "zip": "91324", "country": "United States", "geoPoint": {"lat": 34.22834, "lon": -118.53675}}, {"facility": "Research Site", "city": "Palm Desert", "state": "California", "zip": "92260", "country": "United States", "geoPoint": {"lat": 33.72255, "lon": -116.37697}}, {"facility": "Research Site", "city": "Westminster", "state": "California", "zip": "92683", "country": "United States", "geoPoint": {"lat": 33.75918, "lon": -118.00673}}, {"facility": "Research Site", "city": "Tampa", "state": "Florida", "zip": "33607", "country": "United States", "geoPoint": {"lat": 27.94752, "lon": -82.45843}}, {"facility": "Research Site", "city": "Savannah", "state": "Georgia", "zip": "31406", "country": "United States", "geoPoint": {"lat": 32.08354, "lon": -81.09983}}, {"facility": "Research Site", "city": "Omaha", "state": "Nebraska", "zip": "68114", "country": "United States", "geoPoint": {"lat": 41.25626, "lon": -95.94043}}, {"facility": "Research Site", "city": "Northfield", "state": "New Jersey", "zip": "08225", "country": "United States", "geoPoint": {"lat": 39.37039, "lon": -74.55015}}, {"facility": "Research Site", "city": "Cincinnati", "state": "Ohio", "zip": "45231", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Research Site", "city": "Edmond", "state": "Oklahoma", "zip": "73034", "country": "United States", "geoPoint": {"lat": 35.65283, "lon": -97.4781}}, {"facility": "Research Site", "city": "Medford", "state": "Oregon", "zip": "97504", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "Research Site", "city": "Dallas", "state": "Texas", "zip": "75235", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Research Site", "city": "McKinney", "state": "Texas", "zip": "75069", "country": "United States", "geoPoint": {"lat": 33.19762, "lon": -96.61527}}, {"facility": "Research Site", "city": "San Antonio", "state": "Texas", "zip": "78221", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Research Site", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Research Site", "city": "Calgary", "state": "Alberta", "zip": "T2N 1N4", "country": "Canada", "geoPoint": {"lat": 51.05011, "lon": -114.08529}}, {"facility": "Research Site", "city": "Ajax", "state": "Ontario", "zip": "L1S 2J5", "country": "Canada", "geoPoint": {"lat": 43.85012, "lon": -79.03288}}, {"facility": "Research Site", "city": "Burlington", "state": "Ontario", "zip": "L7N 3V2", "country": "Canada", "geoPoint": {"lat": 43.38621, "lon": -79.83713}}, {"facility": "Research Site", "city": "Mississauga", "state": "Ontario", "zip": "L5A 3V4", "country": "Canada", "geoPoint": {"lat": 43.5789, "lon": -79.6583}}, {"facility": "Research Site", "city": "Ottawa", "state": "Ontario", "zip": "K1G 6C6", "country": "Canada", "geoPoint": {"lat": 45.41117, "lon": -75.69812}}, {"facility": "Research Site", "city": "Windsor", "state": "Ontario", "zip": "N8X 2G1", "country": "Canada", "geoPoint": {"lat": 42.30008, "lon": -83.01654}}, {"facility": "Research Site", "city": "Montreal", "state": "Quebec", "zip": "H3G 1L5", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Research Site", "city": "Trois-Rivieres", "state": "Quebec", "zip": "G8T 7A1", "country": "Canada", "geoPoint": {"lat": 46.34515, "lon": -72.5477}}, {"facility": "Research Site", "city": "Quebec", "zip": "G1V 4G5", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Research Site", "city": "Quebec", "zip": "G1V 4W2", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Research Site", "city": "Chuo-ku", "zip": "103-0027", "country": "Japan", "geoPoint": {"lat": 35.57779, "lon": 139.71685}}, {"facility": "Research Site", "city": "Fukuoka-shi", "zip": "811-1394", "country": "Japan", "geoPoint": {"lat": 33.6, "lon": 130.41667}}, {"facility": "Research Site", "city": "Bia\u0142ystok", "zip": "15-430", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Research Site", "city": "Krak\u00f3w", "zip": "31-011", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Research Site", "city": "Pozna\u0144", "zip": "60-685", "country": "Poland", "geoPoint": {"lat": 52.40692, "lon": 16.92993}}, {"facility": "Research Site", "city": "Pozna\u0144", "zip": "60-693", "country": "Poland", "geoPoint": {"lat": 52.40692, "lon": 16.92993}}, {"facility": "Research Site", "city": "Strzelce Opolskie", "zip": "47-100", "country": "Poland", "geoPoint": {"lat": 50.5107, "lon": 18.30056}}, {"facility": "Research Site", "city": "Tarn\u00f3w", "zip": "33-100", "country": "Poland", "geoPoint": {"lat": 50.01381, "lon": 20.98698}}, {"facility": "Research Site", "city": "Wielu\u0144", "zip": "98-300", "country": "Poland", "geoPoint": {"lat": 51.22097, "lon": 18.56964}}, {"facility": "Research Site", "city": "Wroc\u0142aw", "zip": "53-301", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}]}, "referencesModule": {"references": [{"pmid": "33907423", "type": "DERIVED", "citation": "Alpizar S, Megally A, Chen C, Raj A, Downie J, Colice G. Functionality and Performance of an Accessorized Pre-Filled Syringe and an Autoinjector for At-Home Administration of Tezepelumab in Patients with Severe, Uncontrolled Asthma. J Asthma Allergy. 2021 Apr 19;14:381-392. doi: 10.2147/JAA.S305114. eCollection 2021."}], "seeAlsoLinks": [{"label": "Statistical Analysis Plan (SAP)", "url": "https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5180C00011&amp;attachmentIdentifier=34dcbdad-0c68-4350-8ed5-7194d8bb9c97&amp;fileName=D5180C00011-sap-ed-2_(03-Sep-2020)-redacted.pdf&amp;versionIdentifier="}, {"label": "Protocol", "url": "https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5180C00011&amp;attachmentIdentifier=35e421e0-5181-469c-a1b9-577eb9e0d37b&amp;fileName=D5180C00011-csp-v2_-_CI_Redacted.pdf&amp;versionIdentifier="}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "216 subjects randomized to tezepelumab 210 mg Q4W via APFS and tezepelumab 210 mg Q4W via AI. All randomized subjects were treated. 111 (51.4%) were randomized to tezepelumab 210 mg Q4W via APFS and 105 (48.6%) were randomized to tezepelumab 210 mg Q4W via AI.", "recruitmentDetails": "216 subjects randomized in the study.", "groups": [{"id": "FG000", "title": "Teze 210 mg Q4W Via APFS", "description": "Accessorized pre-filled syringe every 4 weeks administered subcutaneously"}, {"id": "FG001", "title": "Teze 210 mg Q4W Via AI", "description": "Autoinjector every 4 weeks administered subcutaneously"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "111"}, {"groupId": "FG001", "numSubjects": "105"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "110"}, {"groupId": "FG001", "numSubjects": "105"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Teze 210 mg Q4W Via APFS", "description": "Accessorized pre-filled syringe every 4 weeks administered subcutaneously"}, {"id": "BG001", "title": "Teze 210 mg Q4W Via AI", "description": "Autoinjector every 4 weeks administered subcutaneously"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "111"}, {"groupId": "BG001", "value": "105"}, {"groupId": "BG002", "value": "216"}]}], "measures": [{"title": "Age, Continuous", "description": "Measure analysis population description for: Full Analysis Set", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "48.5", "spread": "18.1"}, {"groupId": "BG001", "value": "45.8", "spread": "18.3"}, {"groupId": "BG002", "value": "47.2", "spread": "18.2"}]}]}]}, {"title": "Age, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Adolescents (>=12 to <18 years)", "categories": [{"measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "24"}]}]}, {"title": "Adults (>=18 years)", "categories": [{"measurements": [{"groupId": "BG000", "value": "98"}, {"groupId": "BG001", "value": "94"}, {"groupId": "BG002", "value": "192"}]}]}, {"title": "Adults (>=18 to <65 years)", "categories": [{"measurements": [{"groupId": "BG000", "value": "79"}, {"groupId": "BG001", "value": "73"}, {"groupId": "BG002", "value": "152"}]}]}, {"title": "Adults (>=65 years)", "categories": [{"measurements": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "40"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "56"}, {"groupId": "BG001", "value": "52"}, {"groupId": "BG002", "value": "108"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "55"}, {"groupId": "BG001", "value": "53"}, {"groupId": "BG002", "value": "108"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "87"}, {"groupId": "BG001", "value": "82"}, {"groupId": "BG002", "value": "169"}]}]}, {"title": "Black or African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "16"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "16"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "31"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Hispanic or Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "25"}]}]}, {"title": "Not Hispanic or Latino", "categories": [{"measurements": [{"groupId": "BG000", "value": "99"}, {"groupId": "BG001", "value": "92"}, {"groupId": "BG002", "value": "191"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Proportions of HCPs and Subjects/Caregivers Who Successfully Administered Tezepelumab in Clinic or at Home by Device Type", "description": "Successful administration is defined as an injection completed, based on a used/returned (HCP or subject/caregiver) answer of YES to all 5 questions in the administration questionnaire, and satisfactory in vitro evaluation of returned/evaluated devices.", "populationDescription": "Full analysis set - Include all subjects randomised to study treatment who received or attempted to receive at least one dose of investigational product, irrespective of their protocol adherence and continued participation.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Week 0, Week 4, Week 8, Week 12, Week 16, Week 20", "groups": [{"id": "OG000", "title": "Teze 210 mg Q4W Via APFS", "description": "Accessorized pre-filled syringe every 4 weeks administered subcutaneously"}, {"id": "OG001", "title": "Teze 210 mg Q4W Via AI", "description": "Autoinjector every 4 weeks administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "105"}]}], "classes": [{"title": "Week 0 (in clinic)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "105"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "109"}, {"groupId": "OG001", "value": "105"}]}]}, {"title": "Week 4 (in clinic)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "105"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "102"}]}]}, {"title": "Week 8 (in clinic)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "110"}, {"groupId": "OG001", "value": "105"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "110"}, {"groupId": "OG001", "value": "103"}]}]}, {"title": "Week 12 (at home)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "110"}, {"groupId": "OG001", "value": "105"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "110"}, {"groupId": "OG001", "value": "104"}]}]}, {"title": "Week 16 (at home)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "109"}, {"groupId": "OG001", "value": "105"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "104"}, {"groupId": "OG001", "value": "102"}]}]}, {"title": "Week 20 (in clinic)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "109"}, {"groupId": "OG001", "value": "105"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "102"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Score CI", "statisticalComment": "CI at Week 0 (in clinic)", "paramType": "Proportion", "paramValue": "98.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "93.67", "ciUpperLimit": "99.5"}, {"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Score CI", "statisticalComment": "CI at Week 4 (in clinic)", "paramType": "Proportion", "paramValue": "100", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "96.65", "ciUpperLimit": "100"}, {"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Score CI", "statisticalComment": "CI for Week 8 (in clinic)", "paramType": "Proportion", "paramValue": "100.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "96.63", "ciUpperLimit": "100.00"}, {"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Score CI", "statisticalComment": "CI for Week 12 (at home)", "paramType": "Proportion", "paramValue": "100.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "96.63", "ciUpperLimit": "100.00"}, {"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Score CI", "statisticalComment": "CI for Week 16 (at home)", "paramType": "Proportion", "paramValue": "95.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "89.71", "ciUpperLimit": "98.02"}, {"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Score CI", "statisticalComment": "CI for Week 20 (in clinic)", "paramType": "Proportion", "paramValue": "96.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "90.94", "ciUpperLimit": "98.56"}, {"groupIds": ["OG001"], "nonInferiorityType": "OTHER", "statisticalMethod": "Score CI", "statisticalComment": "CI for Week 0 (in clinic)", "paramType": "Proportion", "paramValue": "100.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "96.47", "ciUpperLimit": "100.00"}, {"groupIds": ["OG001"], "nonInferiorityType": "OTHER", "statisticalMethod": "Score CI", "statisticalComment": "CI for Week 4 (in clinic)", "paramType": "Proportion", "paramValue": "97.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "91.93", "ciUpperLimit": "99.02"}, {"groupIds": ["OG001"], "nonInferiorityType": "OTHER", "statisticalMethod": "Score CI", "statisticalComment": "CI for Week 8 (in clinic)", "paramType": "Proportion", "paramValue": "98.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "93.32", "ciUpperLimit": "99.48"}, {"groupIds": ["OG001"], "nonInferiorityType": "OTHER", "statisticalMethod": "Score CI", "statisticalComment": "CI for week 12 (at home)", "paramType": "Proportion", "paramValue": "99.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "94.80", "ciUpperLimit": "99.83"}, {"groupIds": ["OG001"], "nonInferiorityType": "OTHER", "statisticalMethod": "Score CI", "statisticalComment": "CI for Week 16 (at home)", "paramType": "Proportion", "paramValue": "97.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "91.93", "ciUpperLimit": "99.02"}, {"groupIds": ["OG001"], "nonInferiorityType": "OTHER", "statisticalMethod": "Score CI", "statisticalComment": "CI for Week 20 (in clinic)", "paramType": "Proportion", "paramValue": "97.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "91.93", "ciUpperLimit": "99.02"}]}, {"type": "SECONDARY", "title": "Proportions of Used/Returned Devices That Pass Functional Tests and Visual Inspection and Showed no Evidence of Malfunction", "description": "Devices that passed functional tests and visual inspection and showed no evidence of malfunction will be evaluated as functional.\n\nPercentages have been calculated by using the number of used and returned devices at specified visit as denominator.\n\nNote: A few participants had missing devices. One participant had two AI devices at Week 4.", "populationDescription": "Full analysis set - Include all subjects randomised to study treatment who received or attempted to receive at least one dose of investigational product, irrespective of their protocol adherence and continued participation.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_UNITS", "unitOfMeasure": "Devices", "timeFrame": "Week 0, Week 4, Week 8, Week 12, Week 16, Week 20", "typeUnitsAnalyzed": "Devices", "denomUnitsSelected": "Devices", "groups": [{"id": "OG000", "title": "Teze 210 mg Q4W Via APFS", "description": "Accessorized pre-filled syringe every 4 weeks administered subcutaneously"}, {"id": "OG001", "title": "Teze 210 mg Q4W Via AI", "description": "Autoinjector every 4 weeks administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "105"}]}, {"units": "Devices", "counts": [{"groupId": "OG000", "value": "655"}, {"groupId": "OG001", "value": "624"}]}], "classes": [{"title": "Week 0 (in clinic)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "105"}]}, {"units": "Devices", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "105"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "109"}, {"groupId": "OG001", "value": "105"}]}]}, {"title": "Week 4 (in clinic)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "105"}]}, {"units": "Devices", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "106"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "103"}]}]}, {"title": "Week 8 (in clinic)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "105"}]}, {"units": "Devices", "counts": [{"groupId": "OG000", "value": "110"}, {"groupId": "OG001", "value": "105"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "110"}, {"groupId": "OG001", "value": "103"}]}]}, {"title": "Week 12 (at home)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "105"}]}, {"units": "Devices", "counts": [{"groupId": "OG000", "value": "110"}, {"groupId": "OG001", "value": "104"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "110"}, {"groupId": "OG001", "value": "104"}]}]}, {"title": "Week 16 (at home)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "105"}]}, {"units": "Devices", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "102"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "104"}, {"groupId": "OG001", "value": "102"}]}]}, {"title": "Week 20 (in clinic)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "105"}]}, {"units": "Devices", "counts": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "102"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "105"}, {"groupId": "OG001", "value": "102"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Score CI", "statisticalComment": "CI at Week 0 (in clinic)", "paramType": "Proportion", "paramValue": "98.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "93.67", "ciUpperLimit": "99.50"}, {"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Score CI", "statisticalComment": "CI at Week 4 (in clinic)", "paramType": "Proportion", "paramValue": "100.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "96.65", "ciUpperLimit": "100.00"}, {"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Score CI", "statisticalComment": "CI for Week 8 (in clinic)", "paramType": "Proportion", "paramValue": "100.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "96.63", "ciUpperLimit": "100.00"}, {"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Score CI", "statisticalComment": "CI for Week 12 (at home)", "paramType": "Proportion", "paramValue": "100.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "96.63", "ciUpperLimit": "100.00"}, {"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Score CI", "statisticalComment": "CI for Week 16 (at home)", "paramType": "Proportion", "paramValue": "97.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "92.80", "ciUpperLimit": "99.04"}, {"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Score CI", "statisticalComment": "CI for Week 20 (in clinic)", "paramType": "Proportion", "paramValue": "99.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "94.85", "ciUpperLimit": "99.83"}, {"groupIds": ["OG001"], "nonInferiorityType": "OTHER", "statisticalMethod": "Score CI", "statisticalComment": "CI for Week 0 (in clinic)", "paramType": "Proportion", "paramValue": "100.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "96.46", "ciUpperLimit": "100.00"}, {"groupIds": ["OG001"], "nonInferiorityType": "OTHER", "statisticalMethod": "Score CI", "statisticalComment": "CI for Week 4 (in clinic)", "paramType": "Proportion", "paramValue": "97.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "93.38", "ciUpperLimit": "99.48"}, {"groupIds": ["OG001"], "nonInferiorityType": "OTHER", "statisticalMethod": "Other CI", "statisticalComment": "CI for Week 8 (in clinic)", "paramType": "Proportion", "paramValue": "98.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "93.32", "ciUpperLimit": "99.48"}, {"groupIds": ["OG001"], "nonInferiorityType": "OTHER", "statisticalMethod": "Score CI", "statisticalComment": "CI for week 12 (at home)", "paramType": "Proportion", "paramValue": "100.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "96.44", "ciUpperLimit": "100.00"}, {"groupIds": ["OG001"], "nonInferiorityType": "OTHER", "statisticalMethod": "Score CI", "statisticalComment": "CI for Week 16 (at home)", "paramType": "Proportion", "paramValue": "100.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "96.37", "ciUpperLimit": "100.00"}, {"groupIds": ["OG001"], "nonInferiorityType": "OTHER", "statisticalMethod": "Score CI", "statisticalComment": "CI for Week 20 (in clinic)", "paramType": "Proportion", "paramValue": "100.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "96.37", "ciUpperLimit": "100.00"}]}, {"type": "SECONDARY", "title": "Proportions of Devices That Have Been Reported as Malfunctioning (Product Complaints)", "description": "Performance is measured by the proportion of APFS or AI devices that have been reported as malfunctioning (i.e. via Product Complaints).\n\nPercentages have been calculated by using the number of used and returned devices at specified visit as denominator.\n\nNote: A few participants had missing devices. One participant had two AI devices at Week 4.", "populationDescription": "Full analysis set - Include all subjects randomised to study treatment who received or attempted to receive at least one dose of investigational product, irrespective of their protocol adherence and continued participation.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_UNITS", "unitOfMeasure": "Devices", "timeFrame": "Week 0, Week 4, Week 8, Week 12, Week 16, Week 20", "typeUnitsAnalyzed": "Devices", "denomUnitsSelected": "Devices", "groups": [{"id": "OG000", "title": "Teze 210 mg Q4W Via APFS", "description": "Accessorized pre-filled syringe every 4 weeks administered subcutaneously"}, {"id": "OG001", "title": "Teze 210 mg Q4W Via AI", "description": "Autoinjector every 4 weeks administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "105"}]}, {"units": "Devices", "counts": [{"groupId": "OG000", "value": "655"}, {"groupId": "OG001", "value": "624"}]}], "classes": [{"title": "Week 0 (in clinic)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "105"}]}, {"units": "Devices", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "105"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Week 4 (in clinic)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "105"}]}, {"units": "Devices", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "106"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "Week 8 (in clinic)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "110"}, {"groupId": "OG001", "value": "105"}]}, {"units": "Devices", "counts": [{"groupId": "OG000", "value": "110"}, {"groupId": "OG001", "value": "105"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Week 12 (at home)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "110"}, {"groupId": "OG001", "value": "104"}]}, {"units": "Devices", "counts": [{"groupId": "OG000", "value": "110"}, {"groupId": "OG001", "value": "104"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Week 16 (at home)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "102"}]}, {"units": "Devices", "counts": [{"groupId": "OG000", "value": "107"}, {"groupId": "OG001", "value": "102"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Week 20 (in clinic)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "102"}]}, {"units": "Devices", "counts": [{"groupId": "OG000", "value": "106"}, {"groupId": "OG001", "value": "102"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Score CI", "statisticalComment": "CI at Week 0 (in clinic)", "paramType": "Proportion", "paramValue": "1.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.50", "ciUpperLimit": "6.33"}, {"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Score CI", "statisticalComment": "CI at Week 4 (in clinic)", "paramType": "Proportion", "paramValue": "0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0", "ciUpperLimit": "3.35"}, {"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Score CI", "statisticalComment": "CI for Week 8 (in clinic)", "paramType": "Proportion", "paramValue": "0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0", "ciUpperLimit": "3.37"}, {"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Score CI", "statisticalComment": "CI for Week 12 (at home)", "paramType": "Proportion", "paramValue": "0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0", "ciUpperLimit": "3.37"}, {"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Score CI", "statisticalComment": "CI for Week 16 (at home)", "paramType": "Proportion", "paramValue": "2.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.96", "ciUpperLimit": "7.92"}, {"groupIds": ["OG000"], "nonInferiorityType": "OTHER", "statisticalMethod": "Score CI", "statisticalComment": "CI for Week 20 (in clinic)", "paramType": "Proportion", "paramValue": "0.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.17", "ciUpperLimit": "5.15"}, {"groupIds": ["OG001"], "nonInferiorityType": "SUPERIORITY", "statisticalMethod": "Score CI", "statisticalComment": "CI for Week 0 (in clinic)", "paramType": "Proportion", "paramValue": "0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0", "ciUpperLimit": "3.53"}, {"groupIds": ["OG001"], "nonInferiorityType": "OTHER", "statisticalMethod": "Score CI", "statisticalComment": "CI for Week 4 (in clinic)", "paramType": "Proportion", "paramValue": "2.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.97", "ciUpperLimit": "7.99"}, {"groupIds": ["OG001"], "nonInferiorityType": "OTHER", "statisticalMethod": "Other CI", "statisticalComment": "CI for Week 8 (in clinic)", "paramType": "Proportion", "paramValue": "1.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.52", "ciUpperLimit": "6.68"}, {"groupIds": ["OG001"], "nonInferiorityType": "OTHER", "statisticalMethod": "Score CI", "statisticalComment": "CI for week 12 (at home)", "paramType": "Proportion", "paramValue": "0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0", "ciUpperLimit": "3.56"}, {"groupIds": ["OG001"], "nonInferiorityType": "OTHER", "statisticalMethod": "Score CI", "statisticalComment": "CI for Week 16 (at home)", "paramType": "Proportion", "paramValue": "0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0", "ciUpperLimit": "3.63"}, {"groupIds": ["OG001"], "nonInferiorityType": "OTHER", "statisticalMethod": "Score CI", "statisticalComment": "CI for Week 20 (in clinic)", "paramType": "Proportion", "paramValue": "0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0", "ciUpperLimit": "3.63"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Asthma Control Questionnaire-6 (ACQ-6) Score", "description": "The ACQ-6 captures asthma symptoms and short-acting \u03b22-agonist use via subject-report. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The ACQ-6 score is the mean of the responses.", "populationDescription": "Full Analysis Set - Include all subjects randomised to study treatment who received or attempted to receive at least one dose of investigational product, irrespective of their protocol adherence and continued participation.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Score", "timeFrame": "Baseline (Week 0), Week 4, Week 8, Week 12, Week 16, Week 20 and Week 24", "groups": [{"id": "OG000", "title": "Teze 210 mg Q4W Via APFS", "description": "Accessorized pre-filled syringe every 4 weeks administered subcutaneously"}, {"id": "OG001", "title": "Teze 210 mg Q4W Via AI", "description": "Autoinjector every 4 weeks administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "105"}]}], "classes": [{"title": "ACQ-6 score at Baseline (Week 0)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "105"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.227", "spread": "0.732"}, {"groupId": "OG001", "value": "2.081", "spread": "0.625"}]}]}, {"title": "ACQ-6 score at Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "105"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.629", "spread": "0.791"}, {"groupId": "OG001", "value": "1.492", "spread": "0.715"}]}]}, {"title": "Change from Baseline of ACQ-6 score at Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "105"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.598", "spread": "0.702"}, {"groupId": "OG001", "value": "-0.589", "spread": "0.694"}]}]}, {"title": "ACQ-6 score at Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "105"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.401", "spread": "0.859"}, {"groupId": "OG001", "value": "1.316", "spread": "0.744"}]}]}, {"title": "Change from Baseline of ACQ-6 score at Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "105"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.826", "spread": "0.833"}, {"groupId": "OG001", "value": "-0.765", "spread": "0.793"}]}]}, {"title": "ACQ-6 score at Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "110"}, {"groupId": "OG001", "value": "105"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.197", "spread": "0.751"}, {"groupId": "OG001", "value": "1.143", "spread": "0.745"}]}]}, {"title": "Change from Baseline of ACQ-6 score at Week 12", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "110"}, {"groupId": "OG001", "value": "105"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.011", "spread": "0.805"}, {"groupId": "OG001", "value": "-0.938", "spread": "0.805"}]}]}, {"title": "ACQ-6 score at Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "109"}, {"groupId": "OG001", "value": "105"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.226", "spread": "0.845"}, {"groupId": "OG001", "value": "1.171", "spread": "0.782"}]}]}, {"title": "Change from Baseline of ACQ-6 score at Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "109"}, {"groupId": "OG001", "value": "105"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.986", "spread": "0.893"}, {"groupId": "OG001", "value": "-0.910", "spread": "0.867"}]}]}, {"title": "ACQ-6 score at Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}, {"groupId": "OG001", "value": "105"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.230", "spread": "0.832"}, {"groupId": "OG001", "value": "1.238", "spread": "0.795"}]}]}, {"title": "Change from Baseline of ACQ-6 score at Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}, {"groupId": "OG001", "value": "105"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.978", "spread": "0.866"}, {"groupId": "OG001", "value": "-0.843", "spread": "0.910"}]}]}, {"title": "ACQ-6 score at Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "109"}, {"groupId": "OG001", "value": "105"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.072", "spread": "0.755"}, {"groupId": "OG001", "value": "1.140", "spread": "0.765"}]}]}, {"title": "Change from Baseline of ACQ-6 score at Week 24", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "109"}, {"groupId": "OG001", "value": "105"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.141", "spread": "0.845"}, {"groupId": "OG001", "value": "-0.941", "spread": "0.775"}]}]}]}, {"type": "SECONDARY", "title": "Serum Trough Concentrations", "description": "PK serum samples were collected pre-dose on dosing visits", "populationDescription": "PK analysis set - Includes all subjects in the full analysis set who received tezepelumab treatment and had at least one sample with one detectable serum concentration from a sample collected post-treatment that is assumed not to be affected by factors such as protocol deviations (e.g. disallowed medication or incorrect study medication received).", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "\u00b5g/mL", "timeFrame": "Baseline (Week 0), Week 4, Week 20 and Week 24 (EOT)", "groups": [{"id": "OG000", "title": "Teze 210 mg Q4W Via APFS", "description": "Accessorized pre-filled syringe every 4 weeks administered subcutaneously"}, {"id": "OG001", "title": "Teze 210 mg Q4W Via AI", "description": "Autoinjector every 4 weeks administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "105"}]}], "classes": [{"title": "Baseline (Week 0)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "105"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "spread": "NA", "comment": "\\<LLOQ (Lower Limit of Quantification)"}, {"groupId": "OG001", "value": "NA", "spread": "NA", "comment": "\\<LLOQ (Lower Limit of Quantification)"}]}]}, {"title": "Week 4", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "109"}, {"groupId": "OG001", "value": "105"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "10.9764", "spread": "48.3948"}, {"groupId": "OG001", "value": "10.5690", "spread": "57.0076"}]}]}, {"title": "Week 20", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "108"}, {"groupId": "OG001", "value": "105"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "18.9653", "spread": "69.0785"}, {"groupId": "OG001", "value": "20.3206", "spread": "56.5858"}]}]}, {"title": "Week 24 (EOT)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "109"}, {"groupId": "OG001", "value": "105"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "19.6274", "spread": "58.2660"}, {"groupId": "OG001", "value": "19.9264", "spread": "54.3198"}]}]}]}, {"type": "SECONDARY", "title": "Anti-drug Antibodies (ADA)", "description": "Anti-drug antibodies (ADA) responses at baseline and/or post baseline. Treatment-induced ADA positive is defined as ADA negative at baseline and post-baseline ADA positive. Treatment-boosted ADA positive is defined as baseline positive ADA titre that was boosted to a 4-fold or higher-level following IP administration. Treatment-emergent ADA (TE-ADA) positive is defined as either treatment-induced ADA positive or treatment-boosted ADA positive. ADA incidence is the proportion of TE-ADA positive subjects in a population. Persistently positive is defined as ADA positive at \\>=2 post-baseline assessments (with \\>=16 weeks between first and last positive) or ADA positive at last post-baseline assessment. Transiently positive is defined as having at least one post-baseline ADA positive assessment and not fulfilling the conditions of persistently positive", "populationDescription": "Safety analysis set - Includes all subjects who received at least one dose of tezepelumab.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Pre-treatment on dosing days until end of follow-up (Week 36) per protocol", "groups": [{"id": "OG000", "title": "Teze 210 mg Q4W Via APFS", "description": "Accessorized pre-filled syringe every 4 weeks administered subcutaneously"}, {"id": "OG001", "title": "Teze 210 mg Q4W Via AI", "description": "Autoinjector every 4 weeks administered subcutaneously"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "105"}]}], "classes": [{"title": "ADA positive at baseline and/or post-baseline (ADA prevalence)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "11"}]}]}, {"title": "TE-ADA positive (ADA incidence)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "8"}]}]}, {"title": "Treatment-induced ADA positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "8"}]}]}, {"title": "Treatment-boosted ADA positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "ADA persistently positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "7"}]}]}, {"title": "ADA transiently positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "3"}]}]}, {"title": "Only baseline ADA positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Both baseline and at least one post-baseline ADA positive", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "timeFrame": "From first dose till end of study (Week 36)", "eventGroups": [{"id": "EG000", "title": "Teze 210 mg Q4W Via APFS", "description": "Accessorized pre-filled syringe every 4 weeks administered subcutaneously", "deathsNumAffected": 0, "deathsNumAtRisk": 111, "seriousNumAffected": 5, "seriousNumAtRisk": 111, "otherNumAffected": 29, "otherNumAtRisk": 111}, {"id": "EG001", "title": "Teze 210 mg Q4W Via AI", "description": "Autoinjector every 4 weeks administered subcutaneously", "deathsNumAffected": 0, "deathsNumAtRisk": 105, "seriousNumAffected": 4, "seriousNumAtRisk": 105, "otherNumAffected": 29, "otherNumAtRisk": 105}], "seriousEvents": [{"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 105}]}, {"term": "Pancreatitis acute", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 105}]}, {"term": "Diverticulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 105}]}, {"term": "Escherichia urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 105}]}, {"term": "Genitourinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 105}]}, {"term": "Pneumonia escherichia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 105}]}, {"term": "Varicella", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 105}]}, {"term": "Psychogenic seizure", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 105}]}, {"term": "Renal colic", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 105}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 4, "numAffected": 3, "numAtRisk": 105}]}, {"term": "Haemoptysis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 105}]}, {"term": "Pneumothorax", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 105}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 13, "numAffected": 12, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 15, "numAffected": 15, "numAtRisk": 105}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 6, "numAffected": 4, "numAtRisk": 105}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 11, "numAffected": 9, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 9, "numAffected": 8, "numAtRisk": 105}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 6, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 105}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": true}, "pointOfContact": {"title": "Global Clinical Head", "organization": "AstraZeneca", "email": "information.center@astrazeneca.com", "phone": "+1 877-240-9479"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2019-07-03", "uploadDate": "2021-05-21T08:41", "filename": "Prot_000.pdf", "size": 1417863}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2020-09-03", "uploadDate": "2021-05-21T08:41", "filename": "SAP_001.pdf", "size": 656121}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2021-06-18", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000000911", "term": "Antibodies, Monoclonal"}], "ancestors": [{"id": "D000007155", "term": "Immunologic Factors"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M10184", "name": "Immunoglobulins", "relevance": "LOW"}, {"id": "M4225", "name": "Antibodies", "relevance": "LOW"}, {"id": "M4230", "name": "Antibodies, Monoclonal", "asFound": "Acceleration", "relevance": "HIGH"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}